

IN THE MATTER OF * **BEFORE THE MARYLAND**
CITY ACCESS PHARMACY * **STATE BOARD OF**
PERMIT NO. P08345 * **PHARMACY**
* **Case No. 23-340**

* * * * *

SUPPLEMENTAL ORDER

WHEREAS, the Maryland Board of Pharmacy (the “Board”) entered into a Pre-Charge Consent Order with City Access Pharmacy (the “Pharmacy”) on May 15, 2023;

WHEREAS, the Pre-Charge Consent Order required, among other things, that the Pharmacy cease all sterile compounding operations unless and until: (a) Pharmacist A, the owner and manager, satisfactorily completed USP 797 training by a Board-approved training organization and submitted written proof of completion to the Board; and (b) the Pharmacy submitted to a Board inspection to ensure compliance with USP 797 requirements prior to re-commencing sterile compounding operations;

WHEREAS, on June 12, 2023, Pharmacist A submitted documentation evidencing his successful completion of USP 797 training by a Board-approved training organization;

WHEREAS, on July 20, 2023, the Pharmacy underwent annual and sterile compounding inspections by the Board which indicated that the Pharmacy’s USP and other facility deficiencies had been addressed;

WHEREAS, the Pharmacy has complied with all other conditions set forth in the Pre-Charge Consent Order;

WHEREAS, the Board reviewed the above submission and inspections, and subsequently voted to approve the Pharmacy’s request to re-commence its sterile compounding operations

with terms as set forth below.

ORDER

Based on an affirmative vote of the Board, it is this 10th day of October, 2023, hereby,

ORDERED that the Pharmacy may commence sterile compounding operations upon the date of this Supplemental Order; and be it further,

ORDERED that the Pharmacy's operations, and in particular the Pharmacy's sterile and non-sterile compounding practices, are subject to inspection by the Board; and be it further,

ORDERED that the Board may initiate disciplinary or emergency action against the Pharmacy should further inspections or any environmental or quality assurance test results indicate deficiencies which may pose a risk to public health and safety; and be it further,

ORDERED that this document constitutes a final order of the Maryland State Board of Pharmacy and is therefore a public document for purposes of public disclosure, pursuant to the Public Information Act, General Provisions Art. § 4-333 and COMAR 10.34.01, and shall be posted and reported in accordance with State and federal laws.

10-10-23
Date


Deena Speights-Napata, M.A.
Executive Director